Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products of vancomycin

BMC Clinical Pharmacology

Volumn 11, Issue , 2011, Pages

  Diaz, Jorge A ^a   Silva, Edelberto ^a   Arias, Maria J ^b   Garzón, María ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Vitalis Pharmaceutical   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; PRESCRIPTION DRUG;

ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ASSAY; COMMERCIAL PHENOMENA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG POTENCY; DRUG RESISTANCE; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PHARMACEUTICS; SAMPLE; STATISTICAL ANALYSIS; VALIDATION PROCESS; ANTIBIOTIC RESISTANCE; BACTERIUM; CHEMISTRY; DRUG EFFECT; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, MICROBIAL; DRUGS, GENERIC; MICROBIAL SENSITIVITY TESTS; PRESCRIPTION DRUGS; VANCOMYCIN;

EID: 79960560738     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-11-9     Document Type: Article

References (10)

1. CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, NATIONAL INSTITUTES OF HEALTH. A Public Health Action Plan to Combat Antimicrobial Resistance., http://www.cdc.gov/drugresistance/pdf/2010/Interagency-Action-Plan-PreClearance-03-2011.pdf
2. THE UNITED STATES PHARMACOPOEIA. XXVII. Biological test and assays 1883, 358. Pharmacopoeia Convention Inc Bronx New York USA.
3. INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Validation of Analytical Procedures: Text and Methodology. Q2 (R1). Current Step 4 version. Parent Guideline dated 27 October 1994 (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005)
4. Jones RN, Fritsche TR, Moet GJ. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease 2008, 61:76-79. 10.1016/j.diagmicrobio.2007.12.010, 18221852.
5. Moeta GJ, Wattersa AA, Sadera HS, Jonesx RN. Expanded studies of piperacillin/Tazobactam formulations: variations among branded product lots and assessment of 46 generics lots. Diagnostic Microbiology and Infectious Disease 2009, 65:319-322. 10.1016/j.diagmicrobio.2009.06.012, 19822271.
6. Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clinical Pharmacology 2009, 9:1. 2640365, 19149891.
7. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga F. Generic products of vancomycin fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010, 54:3271-3279. 10.1128/AAC.01044-09, 2916296, 20547818.
8. Melendez P, Diaz J, Silva E, Gonzales P, Gonzalez P, Moreno E, Amaya P, Serrato N, Saenz E. Estudio comparativo de la actividad antimicrobiana de diferentes presentaciones comerciales de antibióticos de administración intravenosa a través de métodos in vitro. Revista Colombiana de Ciencias Químico-Farmacéuticas 2005, 34.
9. Silva E, Diaz JA, Arias MJ, Hernadez AP, De La Torre A. Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration. BMC Clinical Pharmacology 2010, 10:3. 2830186, 20113478.
10. Lorian V, . (Ed.) Antibiotics in Laboratory Medicine. 1980, 95-98. Williams & Wilkins. Baltimore, (Ed.).